Protocol for the Examination of Specimens From Patients With Carcinoma of the Small Intestine

Version: 4.2.0.0
Protocol Posting Date: June 2021
CAP Laboratory Accreditation Program Protocol Required Use Date: March 2022
The changes included in this current protocol version affect accreditation requirements. The new deadline for implementing this protocol version is reflected in the above accreditation date.

For accreditation purposes, this protocol should be used for the following procedures AND tumor types:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resection</td>
<td>Includes specimens designated segmental resection, pancreaticoduodenectomy (Whipple resection), ileocolic resection</td>
</tr>
<tr>
<td>Tumor Type</td>
<td>Description</td>
</tr>
<tr>
<td>Carcinoma</td>
<td>Including carcinomas arising in the duodenum, jejunum, and ileum</td>
</tr>
</tbody>
</table>

This protocol is NOT required for accreditation purposes for the following:

<table>
<thead>
<tr>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy</td>
</tr>
<tr>
<td>Primary resection specimen with no residual cancer (eg, following neoadjuvant therapy)</td>
</tr>
<tr>
<td>Recurrent tumor</td>
</tr>
<tr>
<td>Cytologic specimens</td>
</tr>
</tbody>
</table>

The following tumor types should NOT be reported using this protocol:

<table>
<thead>
<tr>
<th>Tumor Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinoma of the ampulla (consider Ampullary Carcinoma protocol)</td>
</tr>
<tr>
<td>Well-differentiated neuroendocrine tumor of the duodenum (consider the Duodenal and Ampullary NET protocol)</td>
</tr>
<tr>
<td>Well-differentiated neuroendocrine tumor of the jejunum and ileum (consider the Jejunal and Iliial NET protocol)</td>
</tr>
<tr>
<td>Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocols)</td>
</tr>
<tr>
<td>Gastrointestinal stromal tumor (GIST) (consider the GIST protocol)</td>
</tr>
<tr>
<td>Non-GIST sarcoma (consider the Soft Tissue protocol)</td>
</tr>
</tbody>
</table>

Authors
Lawrence J. Burgart, MD*; William V. Chopp, MD*; Dhanpat Jain, MD*.

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.

* Denotes primary author.
Accreditation Requirements
This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

- **Core data elements** are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is “not applicable” or “cannot be determined.”
- **Conditional data elements** are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.
- **Optional data elements** are identified with “+” and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (i.e., secondary consultation, second opinion, or review of outside case at second institution).

Synoptic Reporting
All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

- Data element: followed by its answer (response), outline format without the paired Data element: Response format is NOT considered synoptic.
- The data element should be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including “Cannot be determined” if appropriate.
- Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
  - Anatomic site or specimen, laterality, and procedure
  - Pathologic Stage Classification (pTNM) elements
  - Negative margins, as long as all negative margins are specifically enumerated where applicable
- The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location

Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report ie, all required elements must be in the synoptic portion of the report in the format defined above.

Summary of Changes

v 4.2.0.0

- General Reformatting
- Revised Margins Section
- Revised Lymph Nodes Section
- Added Distant Metastasis Section
- Removed pTX and pNX Staging Classification
Reporting Template

Protocol Posting Date: June 2021
Select a single response unless otherwise indicated.

CASE SUMMARY: (SMALL INTESTINE)
Standard(s): AJCC-UICC 8

SPECIMEN

Procedure
___ Segmental resection
___ Ileocolic resection
___ Pancreaticoduodenectomy (Whipple resection)
___ Other (specify): _________________
___ Not specified

TUMOR

Tumor Site (Note A)
___ Duodenum: _________________
___ Jejunum: _________________
___ Ileum: _________________
___ Small intestine, not otherwise specified: _________________
___ Other (specify): _________________

Histologic Type (Note B)
___ Adenocarcinoma (not otherwise characterized)
___ Mucinous adenocarcinoma (greater than 50% mucinous)
___ Poorly cohesive cell carcinoma with or without signet-ring cells
___ Medullary carcinoma
___ Adenosquamous carcinoma
___ Squamous cell carcinoma
___ Large cell neuroendocrine carcinoma
___ Small cell neuroendocrine carcinoma
# Select this option only if large cell or small cell cannot be determined.
___ Neuroendocrine carcinoma (poorly differentiated)#
___ Mixed adenocarcinoma-neuroendocrine carcinoma
___ Undifferentiated carcinoma
___ Other histologic type not listed (specify): _________________
+Histologic Type Comment: _________________

Histologic Grade (Note C)
___ G1, well differentiated
___ G2, moderately differentiated
___ G3, poorly differentiated
___ G4, undifferentiated
___ Other (specify): _________________
___ GX, cannot be assessed: _________________
___ Not applicable
Tumor Size
___ Greatest dimension in Centimeters (cm): __________________ cm
+Additional Dimension in Centimeters (cm): ____ x ____ cm
___ Cannot be determined (explain): ____________________________

Tumor Extent
___ High-grade dysplasia / carcinoma in situ
___ Invades lamina propria
___ Invades submucosa
___ Invades muscularis propria
___ Invades through muscularis propria into subserosa, or extends into nonperitonealized perimuscular tissue (mesentery or retroperitoneum) without serosal penetration
___ Perforates visceral peritoneum
___ Directly invades other organ(s) or structure(s)
   ___ Other loops of small intestine
   ___ Mesentery of adjacent loops of bowel
   ___ Abdominal wall (by way of serosa)
For Duodenum Only
___ Pancreas
___ Bile duct
Other
___ Other (specify): ____________________________
___ Cannot be determined: ____________________________
___ Cannot be determined: ____________________________
___ No evidence of primary tumor

Macroscopic Tumor Perforation
___ Not identified
___ Present
___ Cannot be determined: ____________________________

Lymphovascular Invasion
___ Not identified
___ Present
___ Cannot be determined: ____________________________

+Tumor Comment: ____________________________

MARGINS (Note D)

Margin Status for Invasive Carcinoma
___ All margins negative for invasive carcinoma
+Closest Margin(s) to Invasive Carcinoma (select all that apply)
___ Proximal: ____________________________
___ Distal: ____________________________
___ Radial or mesenteric: ____________________________
___ Uncinate (retroperitoneal / superior mesenteric artery): ____________________________
___ Bile duct: ____________________________
___ Pancreatic: ____________________________
**Distance from Invasive Carcinoma to Closest Margin**

*Specify in Centimeters (cm)*

- Exact distance in cm: _________________ cm
- Greater than 1 cm

*Specify in Millimeters (mm)*

- Exact distance in mm: _________________ mm
- Greater than 10 mm

**Invasive carcinoma present at margin**

**Margin(s) Involved by Invasive Carcinoma (select all that apply)**

- Proximal: _________________
- Distal: _________________
- Radial or mesenteric (tumor present 0-1 mm from margin): _________________
- Uncinate (retroperitoneal / superior mesenteric artery) (tumor present 0-1 mm from margin):
  - _________________
- Bile duct: _________________
- Pancreatic: _________________
- Other (specify): _________________
- Cannot be determined: _________________

**Margin Status for Dysplasia (select all that apply)**

- All margins negative for carcinoma in situ (high-grade dysplasia) / adenoma
- Carcinoma in situ (high-grade dysplasia) present at margin

**Margin(s) Involved by Carcinoma in Situ (select all that apply)**

- Proximal: _________________
- Distal: _________________
- Other (specify): _________________
- Cannot be determined: _________________

**Margin(s) Involved by Adenoma (select all that apply)**

- Proximal: _________________
- Distal: _________________
- Other (specify): _________________
- Cannot be determined: _________________

**Regional Lymph Nodes**

**Regional Lymph Node Status**

- Not applicable (no regional lymph nodes submitted or found)
Regional lymph nodes present
___ All regional lymph nodes negative for tumor
___ Tumor present in regional lymph node(s)

**Number of Lymph Nodes with Tumor**
___ Exact number (specify): ______________________
___ At least (specify): ______________________
___ Other (specify): ______________________
___ Cannot be determined (explain): ______________________
___ Other (specify): ______________________
___ Cannot be determined (explain): ______________________

**Number of Lymph Nodes Examined**
___ Exact number (specify): ______________________
___ At least (specify): ______________________
___ Other (specify): ______________________
___ Cannot be determined (explain): ______________________

+Regional Lymph Node Comment: _________________

**DISTANT METASTASIS**

Distant Site(s) Involved, if applicable (select all that apply)
___ Not applicable
___ Non-regional lymph node(s): _________________
___ Liver: _________________
___ Other (specify): _________________
___ Cannot be determined: _________________

**PATHOLOGIC STAGE CLASSIFICATION (pTNM, AJCC 8th Edition) (Note E)**

Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time the report is issued. As per the AJCC (Chapter 1, 8th Ed.) it is the managing physician’s responsibility to establish the final pathologic stage based upon all pertinent information, including but potentially not limited to this pathology report.

**TNM Descriptors (select all that apply)**
___ Not applicable
___ m (multiple primary tumors)
___ r (recurrent)
___ y (post-treatment)

**pT Category**
___ pT not assigned (cannot be determined based on available pathological information)
___ pT0: No evidence of primary tumor
___ pTis: High-grade dysplasia / carcinoma in situ
___ pT1: Tumor invades the lamina propria or submucosa
___ pT1a: Tumor invades the lamina propria
___ pT1b: Tumor invades the submucosa
___ pT1 (subcategory cannot be determined)
___ pT2: Tumor invades the muscularis propria

# For T3 tumors, the nonperitonealized perimuscular tissue is, for the jejunum and ileum, part of the mesentery and, for the duodenum in areas where serosa is lacking, part of the interface with the pancreas.

___ pT3: Tumor invades through the muscularis propria into the subserosa, or extends into nonperitonealized perimuscular tissue (mesentery or retroperitoneum) without serosal penetration#
___ pT4: Tumor perforates the visceral peritoneum or directly invades other organs or structures (e.g., other loops of small intestine, mesentery of adjacent loops of bowel, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct)

**pN Category**
___ pN not assigned (no nodes submitted or found)
___ pN not assigned (cannot be determined based on available pathological information)
___ pN0: No regional lymph node metastasis
___ pN1: Metastasis in one or two regional lymph nodes
___ pN2: Metastasis in three or more regional lymph nodes

**pM Category (required only if confirmed pathologically)**
___ Not applicable - pM cannot be determined from the submitted specimen(s)
___ pM1: Distant metastasis

**ADDITIONAL FINDINGS (Note F)**

+Additional Findings (select all that apply)
___ None identified
___ Adenoma(s)
___ Crohn disease
___ Celiac disease
___ Other polyp(s) (specify type[s]): ___________________
___ Other (specify): ___________________

**SPECIAL STUDIES (Note G)**
For reporting molecular testing and immunohistochemistry for mismatch repair proteins, and for other cancer biomarker testing results, the CAP Colorectal Biomarker Template should be used. Pending biomarker studies should be listed in the Comments section of this report.

**COMMENTS**

Comment(s): ________________
Explanatory Notes

A. Tumor Site
The majority of small intestinal carcinomas arise in the duodenum (64%), most commonly around the ampulla of Vater (Figure 1). Approximately 20% arise in the jejunum and 15% in the ileum. Duodenal location has been implicated as a risk factor for poorer outcome.

Figure 1. Anatomical sites of the small intestine. From: Greene FL et al. Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Atlas (2006) published by Springer Science and Business Media LLC, www.springerlink.com.

References

B. Histologic Type
The most common tumor types arising in the small intestine are adenocarcinomas (24% to 44%), well-differentiated neuroendocrine tumors (20% to 42%), gastrointestinal stromal tumors (7% to 9%), and lymphoma (12% to 27%). Separate CAP cancer protocols apply to well-differentiated neuroendocrine tumors, gastrointestinal stromal tumors, and lymphomas.

For carcinomas of the small intestine, the protocol recommends the histologic classification published by the World Health Organization (WHO).

References
C. Histologic Grade
A histologic grading system for adenocarcinomas based on the extent of glandular formation in the tumor is recommended, as shown below.

- Grade X  Grade cannot be assessed
- Grade 1  Well differentiated (more than 95% of tumor composed of glands)
- Grade 2  Moderately differentiated (50% to 95% of tumor composed of glands)
- Grade 3  Poorly differentiated (less than 50% of tumor composed of glands)

Grade 4 is reserved for small cell neuroendocrine carcinoma and undifferentiated carcinoma (WHO classification).

Most small bowel carcinomas are moderately differentiated, followed by poorly differentiated; a minority are well differentiated. Grade does not appear to be a strong predictor of outcome.1,2

References

D. Margins
For segmental small bowel and ileocolic resections, margins include the proximal, distal, and mesenteric margins of resection. For all small bowel segments, except the duodenum, the mesenteric resection margin is the only pertinent radial margin (Figure 2). For pancreaticoduodenectomy specimens of carcinomas of the duodenum, the proximal margin of stomach or duodenum (pylorus-sparing Whipple resection) and the distal resection margin of duodenum are more biologically relevant than in pancreaticoduodenectomy procedures performed for pancreatic carcinoma and should always be sampled. The nonperitonealized surface of the uncinate process (uncinate margin) constitutes the inferior-posterior retroperitoneal margin of pancreaticoduodenectomy specimens. A perpendicular section through the closest approach of tumor to the margin should be taken. This margin has also been referred to as retroperitoneal margin and superior mesenteric artery margin. Complete en face sections through the pancreatic resection margin and the common bile duct margin should also be taken.

Figure 2. A. Mesenteric margin in small intestine completely encased by peritoneum (dotted line). B. Circumferential margin (dotted line) in portion of proximal duodenum incompletely encased by peritoneum. C. Circumferential margin (dotted line) in retroperitoneal portion of duodenum completely unencased by peritoneum.
E. Pathologic Stage Classification
Surgical resection is the most effective therapy for small intestinal carcinoma, and the best estimation of prognosis is related to the anatomic extent (stage) of disease at the time of resection.

The protocol recommends the TNM staging system of the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) but does not preclude the use of other staging systems.

According to AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically infeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

TNM Descriptors
For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y” and “r” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or after initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor before multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval and is identified by the “r” prefix: rTNM.

T Category Considerations
pTis. For small intestinal carcinomas, ‘carcinoma in situ’ (pTis) as a staging term includes cancer cells confined within the glandular basement membrane (high-grade dysplasia). The term “carcinoma in situ” is not widely applied to glandular neoplastic lesions in the gastrointestinal tract but is retained for tumor registry reporting purposes as specified by law in many states. Tumor invasive into the mucosal lamina propria, up to but not through the muscularis mucosae (intramucosal carcinoma), is classified as pT1a. This designation differs from that for colon, in which tumor extension into the lamina propria is regarded as in situ carcinoma, because of the rich lymphatic network in small intestinal mucosa. Tumor extension through the muscularis mucosae into the submucosa is classified as T1b (Figure 3). T2 tumors invade the muscularis propria (Figure 4), and T3 tumors invade subserosal tissues without extension to the peritoneal (serosal) surface or invasion of adjacent organs (Figure 5).
Figure 3. T1a (left side) with tumor invasion of the lamina propria; T1b (right side) with tumor invasion of the submucosa. From: Greene FL et al. Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the *AJCC Cancer Staging Atlas* (2006) published by Springer Science and Business Media LLC, [www.springerlink.com](http://www.springerlink.com).

Figure 4. T2 is defined as tumor invading the muscularis propria. From: Greene FL et al. Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the *AJCC Cancer Staging Atlas* (2006) published by Springer Science and Business Media LLC, [www.springerlink.com](http://www.springerlink.com).
Figure 5. T3 tumors invade through the muscularis propria into subserosal adipose tissue; T4 tumor perforates the peritoneal (serosal) surface. From: Greene FL et al. Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Atlas (2006) published by Springer Science and Business Media LLC, www.springerlink.com.

Tumor that is adherent to other organs or structures macroscopically is classified as cT4. However, if no tumor is found within the adhesion and no perforation of the visceral peritoneum identified microscopically, the tumor should be assigned pT3.

Tumor in veins or lymphatics does not affect the pT classification.

There are no T4a and T4b subcategories for small intestinal carcinomas in the AJCC 8th edition.
**N Category Considerations**
The regional lymph nodes for the anatomical subsites of the small intestine are as follows:\(^2\)

**Duodenum:** retroperitoneal, hepatic artery, inferior pancreaticoduodenal, and superior mesenteric

**Ileum and jejunum:** cecal (terminal ileum only), ileocecal (terminal ileum only), superior mesenteric, mesenteric, NOS

Submission of lymph nodes for microscopic examination. All grossly negative or equivocal lymph nodes are to be submitted entirely. Grossly positive lymph nodes may be partially submitted for microscopic confirmation of metastasis.

The minimum number of lymph nodes that predicts regional node negativity has not been defined for small intestinal cancers. The pathology report should clearly state the total number of lymph nodes examined and the total number involved by metastases. Data are insufficient to recommend routine use of tissue levels or special/ancillary techniques to detect micrometastases or isolated tumor cells.

**Nonregional lymph nodes.** For microscopic examination of lymph nodes in large resection specimens, lymph nodes must be designated as regional versus nonregional, according to the anatomic location of the tumor. Metastasis to nonregional lymph nodes is classified as distant metastasis and designated as M1. Nonregional lymph nodes include celiac and para-aortic nodes.

**Additional Descriptors**

**Lymphovascular Invasion**
Lymphovascular invasion (LVI) indicates whether microscopic lymphatic and/or vascular invasion is identified in the pathology report. LVI includes lymphatic invasion, vascular invasion, or lymph-vascular invasion. By AJCC/UICC convention, LVI does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category.

**References**

**F. Additional Findings**
Conditions that predispose to small bowel malignancy include Crohn disease, celiac disease, inherited polyposis syndromes (including familial adenomatous polyposis and Peutz-Jeghers syndrome), and Lynch syndrome.

Small intestinal adenocarcinomas in Crohn disease arise in the setting of long-standing ileal inflammation; cumulative risk increases after 10 years of Crohn disease, although absolute risk (2.2% at 25 years) remains low.\(^1\) Signet-ring cell carcinomas appear to be more common in Crohn disease than as de novo small intestinal carcinomas.\(^2\)

Small intestinal carcinomas are more frequent in polyposis syndromes, most notably in familial adenomatous polyposis, in which approximately 2.3% of patients developed a duodenal
adenocarcinoma; most tumors in these patients develop in the periamppullary region, and the duodenum may be carpeted with adenomas. Peutz-Jeghers syndrome is also associated with higher risk of small intestinal carcinoma.

Patients with Lynch syndrome have an approximately 4% lifetime risk of developing a small bowel carcinoma; this risk exceeds that of the normal population by 100-fold. Duodenum and jejunum are the most common primary sites, and the small bowel is the first site of cancer in approximately one-fourth of Lynch syndrome patients who develop small bowel tumors. Histopathologic features of Lynch syndrome-associated small intestinal carcinomas are similar to those of colorectal carcinomas arising in this setting; mucinous carcinomas are overrepresented, and tumors often show a high number of intratumoral lymphocytes and Crohn-like lymphoid reaction.

References

G. Ancillary Procedures
Testing for defects in mismatch repair in small intestinal carcinomas is important for detection of Lynch syndrome. Examination of the tissue for defective DNA mismatch repair should be considered in small intestinal carcinomas regardless of the patient’s age, if other predisposing conditions such as familial adenomatous polyposis coli are absent. In addition, emerging data suggest that the frequency of microsatellite instability in small intestinal carcinomas is approximately equal to that of colon cancer and may be associated with better survival. However, this latter indication for testing is not clearly established and has not been accepted as standard of care.

References